<DOC>
	<DOCNO>NCT00510718</DOCNO>
	<brief_summary>This multi-center open-label dose-escalation study novel compound ( MDV3100 ) treat patient castration-resistant ( hormone-refractory ) prostate cancer . Additional patient enrol expanded cohort dos determine tolerable . Patients tolerate drug progress allow continue look PSA response .</brief_summary>
	<brief_title>A Phase 1 Study MDV3100 Patients With Castration-Resistant ( Hormone-Refractory ) Prostate Cancer</brief_title>
	<detailed_description>This Phase 1 , open-label , uncontrolled , dose-escalation study dose-expansion dos determine tolerate . Patients tolerate drug progress allow continue treatment . The study endpoint safety tolerability pharmacokinetics . PSA value also collect look PSA response .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>1 . Histologically cytologically confirm adenocarcinoma prostate ; 2 . Ongoing androgen deprivation therapy gonadotropin release hormone ( GnRH ) analogue inhibitor , orchiectomy ( i.e. , surgical medical castration ) ; 3 . Progressive disease medical surgical castration , 1 . Metastases brain active epidural disease . ( Note : patient treat epidural disease allow ) ;</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostate</keyword>
	<keyword>Cancer</keyword>
	<keyword>Hormone</keyword>
	<keyword>Refractory</keyword>
	<keyword>Castration</keyword>
</DOC>